News

BioStat® Research
& Development Centre

2026 2025 2024 older
BioStat Expands Its Real-World Data and Real-World Evidence Capabilities
20
November
2026
BioStat Expands Its Real-World Data and Real-World Evidence Capabilities
The BioStat Research and Development Center is expanding its service portfolio to include studies based on data from ...
Eli Lilly Poland Becomes a Partner of the “Obesity Treatment” Section on HaloDoctor.pl
04
November
2026
Eli Lilly Poland Becomes a Partner of the “Obesity Treatment” Section on HaloDoctor.pl
We are pleased to announce that HaloDoctor.pl, a health information portal published by BioStat, has launched a dedic...
Medfile Partners with Croma to Support the Aesthetic Medicine Market
29
May
2026
Medfile Partners with Croma to Support the Aesthetic Medicine Market
Medfile, a medical practice management system developed by the BioStat Research and Development Center, has entered i...
Croma and Medfile Establish Clinicore. Biostat Contributes to the Future of Aesthetic Medicine
29
April
2026
Croma and Medfile Establish Clinicore. Biostat Contributes to the Future of Aesthetic Medicine
The rapid advancement of digital technologies and artificial intelligence is reshaping how healthcare providers o...
We Summarised 2025 at Biostat. Another 12 Months of Growth Behind Us
27
January
2026
We Summarised 2025 at Biostat. Another 12 Months of Growth Behind Us
The year 2025 was a period of intensive development and consistent strengthening of Biostat Research and Development ...
20
November
2026
BioStat Expands Its Real-World Data and Real-World Evidence Capabilities
20
November
2026

BioStat Expands Its Real-World Data and Real-World Evidence Capabilities

The BioStat Research and Development Center is expanding its service portfolio to include studies based on data from routine clinical practice – Real-World Data (RWD) and Real-World Evidence (RWE).

This new area combines the company's more than 20 years of experience in clinical and observational research with the capabilities of Medfile, a system developed within the BioStat Group. The offering is aimed at pharmaceutical companies, medical device manufacturers, research institutions, and public organizations.

Research Experience as a Foundation

BioStat has completed more than 300 studies to date, and its team consists of over 100 experts, including project managers, clinical research associates, statisticians, and data managers. The company uses its own eCRF and eTMF systems and has been conducting observational studies for many years, which are a fundamental approach to generating RWE.

As a result, RWE projects at BioStat are conducted according to the same rigorous standards as clinical trials, including a study protocol, a statistical analysis plan prepared before data analysis, an assessment of data sources' fitness for purpose, and control of confounding factors. These elements determine whether real-world data can generate evidence accepted by regulatory authorities, healthcare payers, or scientific journal reviewers.

Medfile – Bridging Clinical Practice and Research

The second pillar of this new service area is Medfile, an electronic medical records system developed within the BioStat Group for over 15 years. It is used by more than 15,000 physicians and healthcare professionals, who manage approximately half a million patient visits through the platform every month.

This combination gives BioStat a distinctive perspective in the market: we understand both how medical data are generated in everyday clinical practice and what is required to use them in reliable scientific research.

In RWE projects, Medfile can support efficient data collection at participating research sites without the need to manually transfer information into separate forms. It can also facilitate the recruitment of healthcare facilities and physicians interested in participating in research projects.

All projects involving real-world clinical data are conducted in compliance with personal data protection regulations and medical confidentiality requirements. Data are used only on the basis of appropriate permissions and agreements with healthcare facilities, in pseudonymized or anonymized form.

Scope of Services

As part of its expanded offering, BioStat provides:

  • Design of prospective and retrospective observational studies.
  • Development and management of patient registries.
  • Post-Authorization Safety Studies (PASS) and Post-Authorization Efficacy Studies (PAES).
  • Drug utilization studies in routine clinical practice.
  • Assessment of data sources' fitness for specific research questions.
  • Statistical analyses and reports for regulatory authorities, healthcare payers, and scientific publications.

 

Real-world data are becoming just as important as clinical trial results. However, data alone are only the beginning – their true value emerges when they are analyzed with the same level of rigor that we apply to pivotal clinical trials. We combine two decades of research experience with an understanding of everyday clinical practice in healthcare facilities using Medfile.

 

— says Rafał Piszczek, President of the BioStat Research and Development Center.

More information about Real-World Evidence studies and the differences between RWD and RWE is available in the BioStat Knowledge Base.

Companies and institutions planning a research project can schedule a free consultation with BioStat experts.

 

See also
R & D as the driving force for business - an interview with Rafał Piszczek R & D as the driving force for business - an interview with Rafał Piszczek
In the latest release of "Why STORY" an interview with the CEO of BioStat® Rafał Piszczek talks about the driving...
Surveyors labour market in Poland
One of the most important issues covered by the Head Office for Geodesy and Cartography (GUGiK) is education and prof...
Copyright© 2023 Biostat